Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Draft bill proposes rules not only on producing and marketing marijuana, but on using in supplements ingredients derived from cannabis plants classified as hemp. Some supplement industry stakeholders see draft as delivering on industry requests but others say it goes too far.
Can cannabinoids provide therapeutic benefits to consumers? A new animal study by the UK's TTS Pharma suggests anti-inflammatory properties for CBD, according to the company's director of Medical Affairs, Rob Walton.
SōRSE uses proprietary water-soluble emulsion technology to blend cannabinoids into ingredients its customers use in supplements, food and beverages and topicals. Cannabinoids it works with include THC and it also offers its own cannabis-infused beverage brands.
Arizona CBD marketer Kushly Industries is ordered to no longer make disease claims for products without competent and reliable scientific evidence. Settlement lists 16 examples of claims but order in US district court identifies 32 claims the firm acknowledged it used in advertising.
Kentucky's junior senator re-introdd legislation to raise from 0.3% to 1% the level of THC by dry weight that Congress defined as legal hemp in the 2018 farm bill.
Congressional Research Service report says in addition to markets for hemp from fiber, seeds and flowers, “a separate, marketable category exists for the plant’s extracted compounds.” Ingredients from hemp seeds and grains as well as from flowers are alternative protein sources in supplements, foods and beverages and dairy alternatives.
Committee report again includes item concerning FDA’s work on expanding access to opioid antagonist naloxone. It still doesn’t acknowledge agency’s interest in making drug available OTC in a nasal inhaler, but emphasizes access for pregnant and postpartum women.
Appropriation Committee’s report with FDA’s FY2022 funding bill appears to signal that other than getting something done, members have little to say about establishing lawful use of hemp-derived cannabinoids in non-drug products.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.